Bill Gates Others Invest Millions in Alzheimer s Tools
Bill Gates, Others Invest Millions in Alzheimer’s Tools
Alzheimer’s disease, the most common form of dementia, affects almost 6 million Americans and is growing at an alarming rate. There is no known cure for Alzheimer’s, no treatments to halt its progression and no definitive understanding of what causes it. The number of cases of Alzheimer’s and other forms of dementia in the United States is expected to increase to 16 million by 2050.
Last year, Gates announced he would invest $100 million of his own money, not from the Bill & Melinda Gates Foundation, in Alzheimer’s research, putting (DDF). The DDF takes a different approach to dementia research by applying the venture capital model, common in Silicon Valley, to fund research toward new treatments and therapies. Last month, AARP CEO Jo Ann Jenkins announced a to accelerate the search for a cure.
In addition, early detection is critically important to help people adjust to the diagnosis of Alzheimer’s and to improve their quality of life, said Sarah Lock, AARP senior vice president for policy and executive director of the Global Council on Brain Health. “As we have seen in our own research, physicians are reluctant to diagnose the disease,” Lock said. “Early diagnosis is really key to advancing the field.” Editor’s note: This story was updated to add the Alzheimer’s Drug Discovery Foundation, which is a partner in funding the Diagnostic Accelerator.
Cancel You are leaving AARP.org and going to the website of our trusted provider. The provider’s terms, conditions and policies apply. Please return to AARP.org to learn more about other benefits. Your email address is now confirmed. You'll start receiving the latest news, benefits, events, and programs related to AARP's mission to empower people to choose how they live as they age. You can also by updating your account at anytime. You will be asked to register or log in. Cancel Offer Details Disclosures
Bill Gates Announces $30 Million Fund for Alzheimer s Diagnostic Tools
New Diagnostics Accelerator focuses on early detection of the disease
Jack Taylor/Getty Images Bill Gates is ramping up his fight to find : He announced Tuesday that he and other philanthropic investors are contributing $30 million to the Diagnostics Accelerator, a new investment fund dedicated to finding ways to detect and diagnose the disease earlier. “Alzheimer’s research is a frontier where we can dramatically improve human life — both the lives of people who have the disease and their loved ones,” said Gates, who disclosed last year that disease, igniting a passion in him to help find a cure.Alzheimer’s disease, the most common form of dementia, affects almost 6 million Americans and is growing at an alarming rate. There is no known cure for Alzheimer’s, no treatments to halt its progression and no definitive understanding of what causes it. The number of cases of Alzheimer’s and other forms of dementia in the United States is expected to increase to 16 million by 2050.
Last year, Gates announced he would invest $100 million of his own money, not from the Bill & Melinda Gates Foundation, in Alzheimer’s research, putting (DDF). The DDF takes a different approach to dementia research by applying the venture capital model, common in Silicon Valley, to fund research toward new treatments and therapies. Last month, AARP CEO Jo Ann Jenkins announced a to accelerate the search for a cure.
Early detection br
The Diagnostics Accelerator initiative, in a key collaboration with the , will focus on identifying biomarkers of the disease and inventive new technologies. “One of the biggest things we could do right now is develop a reliable, affordable and accessible diagnostic,” Gates said. He wants to imagine a world in which diagnosing Alzheimer’s disease is as simple as getting your blood tested during your annual physical. Current methods are expensive, invasive and usually not undertaken until after symptoms present in patients. Research suggests that "Alzheimer’s starts damaging the brain more than a decade before symptoms start showing. That’s probably when we need to start treating people to have the best shot at an effective drug,” Gates noted.In addition, early detection is critically important to help people adjust to the diagnosis of Alzheimer’s and to improve their quality of life, said Sarah Lock, AARP senior vice president for policy and executive director of the Global Council on Brain Health. “As we have seen in our own research, physicians are reluctant to diagnose the disease,” Lock said. “Early diagnosis is really key to advancing the field.” Editor’s note: This story was updated to add the Alzheimer’s Drug Discovery Foundation, which is a partner in funding the Diagnostic Accelerator.
More on Brain Health
Cancel You are leaving AARP.org and going to the website of our trusted provider. The provider’s terms, conditions and policies apply. Please return to AARP.org to learn more about other benefits. Your email address is now confirmed. You'll start receiving the latest news, benefits, events, and programs related to AARP's mission to empower people to choose how they live as they age. You can also by updating your account at anytime. You will be asked to register or log in. Cancel Offer Details Disclosures